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Abstract 
Background: Cholinergic urticaria (CholU) is a common type of chronic inducible urticaria, characterized by small 
itchy wheals that appear upon physical exercise or passive warming. Malassezia globosa, a skin resident fungus, has 
been identified as an antigen that induces mast cell/basophil degranulation and wheal formation through specific 
IgE, in Japanese patients with atopic dermatitis and CholU. In this study we aimed in assessing the rate of IgE sensiti-
zations against skin resident fungi in European CholU patients.
Methods: We assessed serum IgE levels to Malassezia furfur, Candida albicans and Trichophyton mentagrophytes using 
routine lab testing and Malassezia globosa using a newly established ELISA. We correlated the results to wheal forma-
tion and other clinical features.
Results: Four patients (of 30 tested) had elevated levels of IgE against Malassezia furfur and Candida albicans and two 
had elevated levels of IgE against Trichophyton mentagrophytes. Four sera (of 25 tested) had elevated levels of IgE to 
the Malassezia globosa antigen supMGL_1304. Sensitization to one skin fungus was highly correlated with sensitiza-
tion to the other tested fungi. We saw highly significant correlations of sensitization to supMGL_1304 with wheal size 
in the autologous sweat skin test  (rs = 0.7, P = 0.002, n = 19), the Erlangen atopy score  (rs = 0.5, P = 0.03, n = 19), total 
IgE serum levels  (rs = 0.5, P = 0.04, n = 19) and a positive screen for IgE against common airborne/inhalant allergens s 
(sx1;  rs = 0.54, P = 0.02, n = 19).
Conclusions: Sensitization to skin resident fungi including Malassezia globosa is uncommon in European CholU 
patients, but is associated with atopy and pronounced wheal formation upon dermal contact with their own sweat.
Trial registration German Clinical Trials Registry DRKS-ID: DRKS00004277
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Background
Cholinergic urticaria (CholU) is one of the most com-
mon forms of inducible urticaria and is characterized by 
small itchy wheals that are induced by physical activity or 
passive warming [1–3]. There is a high reported preva-
lence (up to 4%) in the general population [4, 5], with one 
publication mentioning a 20% prevalence in young adults 
[6], although the disease can also start later in life [7]. The 
severity/clinical spectrum of the disease might be broad, 
with some patients suffering from severe disease with 
frequent wheal formation and intolerable itch, which 
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The underlying pathogenesis of CholU is not under-
stood, but several mechanisms have been proposed 
[10, 11]. Many studies have provided evidence that IgE-
mediated mast cell activation is of major importance in 
the pathogenesis of CholU. Patients exhibit high rates 
of atopy [12], which has been linked to higher levels of 
disease activity and to elevated total IgE serum levels. 
CholU is adoptively transferable to healthy subjects by 
injecting CholU patient serum into healthy skin, suggest-
ing a transferable serum factor and antigen–antibody 
driven disease mechanism [13]. It is also well established 
that some CholU patients develop wheal and flare type 
reactions upon skin testing with their own sweat [13], 
pointing towards a type-I allergy against sweat. Further 
evidence that IgE-mediated effects play a major role in 
CholU comes from reports of successful treatment of 
patients with anti-IgE (omalizumab) [14, 15]. Neverthe-
less, the antigen causing the IgE-mediated symptoms in 
CholU was not known for a long time. More recently, 
Hiragun et al. detected elevated levels of IgE against the 
lipophilic yeast-like fungi Malassezia globosa in patients 
with atopic dermatitis and CholU and identified a fre-
quently reactive antigen (supMGL_1304) in human sweat 
[16–18]. Sweat-derived antigens have also been shown to 
be of functional relevance, as these antigens were able to 
induce degranulation of mast cells and basophils in sensi-
tized atopic dermatitis patients [19, 20], a disease where 
skin resident fungi are thought to play an important role 
in the pathogenesis of the disease [21].
These studies were performed in Japan. To date it is not 
known whether patients from other parts of the world 
also show these sensitizations, whether they account for 
the skin reaction with autologous sweat and whether they 
are of clinical relevance. To address this, we analyzed 
specific IgE serum levels to known skin resident fungi, 
including the Malassezia globosa antigen supMGL_1304, 
and correlated the results with wheal formation in the 




In this study, 39 patients with CholU were recruited at 
the UCARE Center [22] of the Department of Derma-
tology and Allergy, Charité-Universitätsmedizin, Ber-
lin for provocation testing, sweat collection, skin testing 
and extensive clinical characterization. Patients were 
advised to stop taking antihistamines at least 3  days 
prior to any tests. None of the patients had taken local 
or systemic glucocorticoids or other immunosuppressive 
therapy 2 weeks before the tests. As a control group, 70 
healthy individuals were recruited and underwent the 
same procedures, except provocation testing. The study 
was approved by the Ethics Committee of the Charité-
Universitätsmedizin Berlin (EA4/124/10), and is regis-
tered in the German Clinical Trials Registry (DRKS-ID: 
DRKS00004277). Other aspects of the study will be pub-
lished elsewhere.
Demographic and clinical characteristics of the patients 
and healthy controls are shown in Table 1.
Clinical assessments
Patients and healthy controls were assessed for their 
clinical history and comorbidities. Atopic skin diath-
esis (atopic predisposition) was also assessed using the 
Erlanger Atopy score questionnaire [23]. For CholU 
patients, disease duration was recorded and disease 
severity was rated using the Cholinergic Urticaria Sever-
ity Index (CholUSI). This is a sum score that takes into 
account the frequency of CholU symptoms (< once 
a month = 0 point; once a month = 1 point; > once a 
month = 2 points; once a week = 3 points; > once a 
week = 4 points; daily = 5 points; > daily = 6 points), 
eliciting factors (one point each for: physical exercise, 
hot bath, hot shower, emotional stress, hot food, sauna, 
other), duration of skin lesions (< 5  min = 0 point; 5 – 
10  min = 1 point; 10–20  min = 2 points; 20–30  min = 3 
points; 30–60  min = 4 points; > 1  h = 5 points) and itch 
(none = 0 point; mild = 1 point; moderate = 2 points; 
severe = 3 points). The CholUSI score ranges from 0 to 21 
points: < 5 points = very mild CholU; 5–9 points = mild 
CholU; 10–15 points = moderate CholU; > 15 
points = severe CholU [24].
Sauna provocation test
After showering without soap and completely drying, 
patients were put in a large plastic bag (polyethylene, 
food safe grade, Ratioform GmbH, Pliening, Germany) 
Table 1 Clinical characteristics of study participants







 Median (IQR) 31.5 (23.3–46.5) 31.0 (27.0–34.0) n.s.
Sex
 M:F 16:23 40:30 n.s.
BMI [kg/m2]
 Median (IQR) 24.2 (20.8–26.7) 22.9 (20.2–24.7) n.s.
Persistance of disease 
[years]
 Median (range) 6.0 (3.0–12.8) – –
Total IgE [kU/l]
 Median (range), 
n = 29
164.0 (46.8–291.0) – –
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that covered the entire body, apart from the head. They 
then took a 15  min sauna at 80  °C, during which sweat 
was collected in the bag. The total sweat volume was 
measured and the sweat was immediately frozen at 
− 20 °C and at − 80 °C for long term storage.
Pulse controlled ergometry test
Eighteen patients underwent pulse controlled ergometry 
testing as described elsewhere [25]. They were assessed 
for the time to onset of sweating using the iodine–starch 
reaction (sweat test according to Minor), the time to 
onset of whealing and the increase in heart rate at the 
onset of whealing. Patients were assessed for their symp-
toms at the end of the test (itching: no itch = 0, mild 
itch = 1, moderate itch = 2, severe itch = 3; whealing: no 
whealing = 0, 1–20 wheals = 1, 21–50 wheals = 2, > 50 
wheals = 3) to result in a urticaria activity score at the 
time of provocation (UASprovo) with a sum score 
between 0 and 6 points.
Skin tests
Skin tests were performed at least 24 h after provocation 
testing. For the ASwST, the patient’s sweat was defrosted 
on the day of testing, sterile filtered using Sartorius™ 
Minisart NML (sterile, Sartorius AG, Göttingen, Ger-
many) and diluted using sterile NaCl 0.9% under sterile 
conditions. The sweat was diluted (1:100) and intracuta-
neously injected (i.c., 50  µl) using a 1  ml syringe (Plas-
tipak™, 1  ml, Becton–Dickinson (BD), Heidelberg, 
Germany) and a needle for subcutaneous injection (27 G 
1/2`, 13 mm, BD), as described by Kozani et al. [21].
For the autologous serum skin test (ASST) [26], 50 µl 
freshly drawn patient serum was injected intradermally. 
For the acetylcholine i.c. (ACh i.c.) test, acetylcholine was 
diluted with NaCl 0.9% solution under sterile conditions 
to a final concentration of 100 µg/ml (0.01%) as described 
by Fukunaga et  al. [27] and injected intradermally. 
Detailed results of the ACh i.c. test will be reported 
elsewhere.
NaCl 0.9% solution and histamine 100  µg/ml (0.01%; 
Bencard Allergie GmbH, Munich, Germany) were used 
for i.c. testing as negative and positive controls, respec-
tively. The diameter of the resulting wheal and flare reac-
tions were measured using a transparent ruler with 1 mm 
grading after 15 min and 30 min. The skin tests were con-
sidered positive if the wheal induced by sweat or ACh 
was ≥ 1.5  mm bigger than that induced by the negative 
control (NaCl 0.9%).
IgE measurements
IgE levels were measured using the Immuno CAP 
 System® (Phadia Laboratory Systems, Thermo Fisher 
Scientific Inc, Uppsala, Sweden) at a central laboratory 
(Labor Berlin GmbH, Berlin, Germany). Serum was 
analysed for total IgE, IgE against common airborne/
inhalant allergens (D1 house dust mite, E1 cat, E5 
dog, G6 timothy, G12 rye, M2 Cladosporium herba-
rum, T3 birch, W6 mugwort), and specific IgE to Can-
dida albicans, Malassezia furfur and Trichophyton 
mentagrophytes.
Total IgE levels > 100 kU/l were considered elevated. 
Specific IgE levels of > 0.1 kU/l were considered as 
detectable, and levels of ≥ 0.35 kU/l as sensitization 
(0.00–0.34 CAP-Class 0, 0.35–0.70 CAP-Class 1, 0.70–
3.50 CAP-Class 2, 3.50 to < 17.5 CAP Class 3, 17.5 to 
< 50.0 CAP Class 4, 50.0–100.0 CAP-Class 5, > 100.0 
CAP-Class 6).
SupMGL_1304 IgE ELISA
IgE against supMGL_1304 from Malassezia globosa 
were detected using an ELISA as described by Kan et al. 
and Hiragun et al. [17, 28]. In brief, 96-well plates (high-
binding, Greiner bio-one, Frickenhausen, Germany) 
were coated with 10 µg/ml mouse monoclonal antibody 
against purified supMGL_1304 (Smith-2 antibody; gener-
ation of antibody has been described in [18] overnight at 
4 °C. Plates were blocked with 2% bovine serum albumin 
in phosphate buffered saline (BSA-PBS) for 1 h at room 
temperature and washed with 0.05% tween20-PBS. The 
coated plates were then incubated with 1 μg/ml purified 
supMGL_1304 in 0.1% BSA-PBS for 90 min at room tem-
perature. Patients’ serum was diluted 1:40 with 1% BSA-
PBS and incubated after washing of the plates at room 
temperature for 90  min. After washing, the plates were 
incubated with peroxidase-labeled antibody to human 
IgE (ε-chain specific, KPL, Gaithersburg, MD, USA) 
diluted 1:3000 with 1% BSA-PBS at room temperature for 
1 h. After washing, TMB Microwell Peroxidase Substrate 
was added and incubated for 30 min. The reactions were 
stopped with TMB Stop Solution (KPL). The optical den-
sity was read at 450 nm using an automatic plate reader 
(Benchmark Plus, Bio-Rad, Hercules, CA, USA). Pooled 
serum of Japanese patients with atopic dermatitis was 
used as standard in various dilutions (1:10 to 1.1208 in 
1% BSA-PBS). Results are given as arbitrary units (AU) in 
correlation with the standard serum.
Statistical analyses
Statistical analyses were performed using IBM SPSS 
Statistics version 23 and GraphPad Prism Version 6.0. 
Binominal variables were analyzed using Chi-square test 
or Fisher Exact test for small categorical numbers (< 5). 
Non-parametric continuous variables were compared 
using Mann–Whitney-U test. Correlations were analyzed 
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using Spearman rank test. P < 0.05 was considered to 
indicate statistical significance.
Results
Sensitization against skin resident fungi can be detected 
in a small population of European CholU patients
Results from the specific IgE testing against the fungi 
Candida albicans a, Malassezia furfur and Trichophyton 
mentagrophytes were available for 30 patients (Fig.  1a). 
Considering 0.1 kU/l as the limit for specific IgE levels, 
four patients (13%) had clearly elevated levels against 
Malassezia furfur. Two patients had IgE levels in the 
CAP-Class 2, and two had IgE levels in the CAP-Class 
3, reaching levels up to 14.2 kU/l. More patients (n = 8; 
26%) had detectable IgE levels against Candida albicans, 
but half of them were in the CAP-Class 0. Three had lev-
els in CAP-Class 2 and one in CAP-Class 3. IgE against 
Trichophyton mentagrophytes. was detected in only three 
patients (10%), with one patient in CAP-Class 0 and two 
in CAP-Class 2.
Specific IgE against Malassezia furfur positivity was 
highly correlated with detectable levels of IgE against 
the other fungi (Candida albicans.:  rs = 0.59, P = 0.001; 
Trichophyton mentagrophytes:  rs = 0.68, P < 0.001).
IgE against the Malassezia globosa antigen supMGL_1304 
was elevated in a small number of CholU patients 
and was well correlated with levels of specific IgE 
against the other skin fungi
Using IgE levels from 20 healthy controls, who reported 
no known sensitization and had a normal low total IgE 
level below 100 kU/l, a cut-off was set at the 95% percen-
tile (19.4 AU).
Of the 25 CholU patients who underwent testing, four 
(12%) had levels of IgE against supMGL_1304 above 
the set 95% percentile, with values ranging from 21.8 to 
1594.5 AU (Fig. 1b). These values showed a high correla-
tion with sensitization against the measured skin resident 
fungi (Malassezia furfur  rs = 0.633, P = 0.013; Candida 
albicans:  rs = 0.548, P = 0.037; Trichophyton mentagro-
phytes:  rs = 0.555, P = 0.042). Three of the four positive 
sera also showed elevated IgE levels to all the other three 
skin resident fungi.
Sensitization to supMGL_1304 was correlated with skin 
reactions against autologous sweat in CholU patients, 
but not with ASST or ACh i.c. positivity
The ASwST (using 1:100 diluted sweat) was performed 
in 38 CholU patients. Twenty-eight patients (73.7%) 
developed a wheal 15 min after injection, compared with 
only one (1.4%) of the 69 healthy controls (P < 0.001). All 
four CholU patients with sensitization to supMGL_1304 
had a positive reaction in the ASwST. Of the 34 patients 
without sensitization to supMGL_1304, 24 (73.5%) had 
a positive reaction. In CholU patients, we saw a highly 
significant correlation of sensitization to supMGL_1304 
with wheal size in the ASwST  (rs = 0.7, P = 0.002, n = 19). 
Fig. 1 Specific IgE levels against skin fungi in CholU patients (n = 30) 
(a), and against supMGL-1304 in CholU patients (n = 25) and healthy 
controls (n = 20) (b). Individual patients are displayed as dots. b 
Shows median and interquartile ranges of specific IgE levels against 
supMGL-1304. 95% percentile calculated from healthy controls is 
represented by a dashed line
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Patients with IgE against supMGL_1304 had significantly 
larger wheals in the ASwST compared with the rest of the 
patients (mean 10.5 ± 2.7 mm vs. 5.0 ± 4.0 mm, P = 0.026; 
Fig. 2). No correlation or differences were seen with the 
wheal size of the histamine positive control (data not 
shown).
Serum autoreactivity and Ach i.c. reactivity were also 
assessed in both CholU patients and healthy controls. 
Twelve (31.6%) of the CholU patients but only 7 (10.1%) 
of the healthy controls showed a positive reaction in the 
ASST (P = 0.008). In contrast to the ASwST, no signifi-
cant correlation with the sensitization to supMGL_1304 
was seen  (rs = −0.44, P = 0.06, n = 19). None of the 
patients with elevated IgE levels to supMGL_1304 had 
a positive reaction in the ASST and only one of these 
patients developed a wheal in the ACh i.c test. However, 
all patients with elevated IgE levels to supMGL_1304 
developed a flare reaction in the ACh i.c. test, compared 
to the remaining patients where only about 50% exhib-
ited such a skin reaction (Table 2).
Sensitization to supMGL_1304 was associated with atopic 
predisposition (Erlangen Atopy score, total IgE)
In CholU patients, levels of IgE against supMGL_1304 
showed a positive correlation with the Erlangen atopy 
score  (rs = 0.53, P = 0.02, n = 19) and with total IgE serum 
levels  (rs = 0.54, P = 0.04, n = 19), but not with sensitiza-
tion to inhalant allergens (SX1  rs = 0.31, P = 0.30, n = 13).
Sensitization to supMGL_1304 was associated with female 
sex and higher UASprovo scores, driven by intensity of itch
All four patients with clearly elevated serum levels of IgE 
anti supMGL_1304 were females. Due to the low num-
bers, interpretation of the statistical significance of these 
results must be made with caution.
Clinically, levels of IgE against supMGL_1304 were 
significantly correlated to the skin reactivity in the pulse 
controlled ergonometry test. There was a good and 
significant correlation with the UASprovo sum score 
 (rs = 0.84, P = 0.004, n = 10). Analysis of the wheal and 
itch scores revealed that this correlation was driven by 
itch  (rs = 0.84, P = 0.006, n = 10), but not wheal  (rs = 0.41, 
P = 0.40, n = 10), indicating that sensitization to sup-
MGL_1304 was associated with more severe itch in the 
CholU patients.
No correlation was seen with age, disease persistance, 
frequency of symptoms or factors that trigger sweat-
ing (data not shown). Specific IgE levels against sup-
MGL_1304 in CholU patients were negatively correlated 
with body weight  (rs = −  0.55, P = 0.02, n = 19), indicat-
ing that sensitization to supMGL_1304 is not associated 
with large skin surface area/obesity.
Discussion
To our knowledge, this is the first screening of CholU 
patients for specific IgE against skin fungi in European 
CholU patients. Sensitization to Malassezia globosa is 
well documented in Japanese patients [17].
We found that a small subgroup of patients (up to 26%) 
have IgE against Candida albicans, Malassezia furfur 
and Trichophyton mentagrophytes. Interestingly, there 
was a high correlation between sensitization to the dif-
ferent fungi, indicating that there is a subgroup of CholU 
patients who are prone to sensitization against skin resi-
dent fungi. In patients with atopic dermatitis, skin resi-
dent fungi are thought to play an important role in the 
pathogensis of the disease via altered cytokine responses 
to the fungus [29, 30]. Whether similar responses are 
induced in CholU has not yet been investigated.
The proportion of patients with elevated serum levels 
of IgE against Malassezia globosa was considerably lower 
in our study than in a previous study of Japanese patients 
[17] (12% vs. 58%). This may be due to the difference in 
climate between Germany and Japan, which could lead to 
lower levels of Malassezia globosa colonization in Ger-
man patients [31, 32]. Alternatively, there may be genetic 
differences between the German Caucasian and Japanese 
populations that affect sensitivity to skin resident fungi.
In our study, patients with sensitization to sup-
MGL_1304 had more pronounced skin reactions in 
the ASwST and a correlation of the wheal size in the 
ASwST with levels of IgE against supMGL_1304. Several 
Fig. 2 Skin reactivity in the ASwST with histamine as positive and 
NaCl as negative controls. Differences between the CholU patients 
with elevated specific IgE levels against supMGL-1304 (MG+; n = 4) 
and CholU patients with normal low supMGL-1304 (MG−, n = 21) 
are shown. Median and interquartile ranges of the largest wheal size 
measured are depicted
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Table 2 Clinical characteristics of CholU patients with elevated specific IgE levels against supMGL-1304 (MG+) and CholU 







 Median (range) 35.5 (21–57) 31.0 (18–55)
 Mean ± SD 37.3 ± 9.0 32.9 ± 2.5 0.504
Sex
 M:F 0:4 11:10 0.105
BMI [kg/m2]
 Median (range) 21.4 (20.2–25.2) 24.7 (20.0–32.3)
 Mean ± SD 22.1 ± 1.1 25.1 ± 0.8 0.119
Clinical data
 Persistence of disease [years]
  Median (range) 3.5 (1.0–29.0) 5.0 (1.0–20.0)
  Mean ± SD 9.3 ± 6.6 7.6 ± 1.3 0.681
 CholUSI n = 19
  Median (range) 16.5 (15–19) 16.0 (10–20)
  Mean ± SD 16.7 ± 0.8 16.0 ± 0.5 0.540
 UAS Provo n = 3 n = 10
  Median (range) 5 (5, 6) 4 (3–5)
  Mean ± SD 5.3 ± 0.5 4.1 ± 0.7 0.036
 Itch Score Provo n = 3 n = 10
  Median (range) 2 (2, 3) 1 (1, 2)
  Mean ± SD 2.3 ± 0.5 1.3 ± 0.5 0.069
 Wheal Score Provo n = 3 n = 10
  Median (range) 3 (3) 3 (2, 3)
  Mean ± SD 3 ± 0 2.8 ± 0.4 0.167
Atopic features
 Erlangen Atopy score n = 20
  Median (range), 14.5 (12–20) 9.0 (5–14)
  Mean ± SD 15.3 ± 1.7 9.0 ± 0.7 0.026
 Total IgE [kU/l] n = 15
  Median (range) 1360.5 (278.0–4377.0) 71.9 (14.8–600.0)
  Mean ± SD 1844.0 ± 886.0 154.5 ± 169.2 0.152
 Pos. Sx1 screening (inhalative allergen mix) n = 3 n = 15
2 (67%) 9 (60%) 1.0
 Pos. sIgE to other skin resident fungi n = 17
3 (75%) 1 (6.3%) 0.012
Skin testings
 ASwST 1:100 pos. (n) 4 (100%) 15 (71%) 0.540
 ASwST wheal size diameter (mm) n = 20
  Median (range) 9.5 (0.8–1.5) 5.5 (0–1.3)
  Mean ± SD 10.5 ± 2.7 5.6 ± 4.2 0.04
 ASwST flare size diameter (mm) n = 20
  Median (range) 33.5 (1.4–3.7) 12.0 (0–4.5)
  Mean ± SD 29.5 ± 0.9 17 ± 4 0.060
 ASST pos (n) 0 (0%) 5 (24%) 0.55
 ASST wheal size diameter (mm) n = 20
  Median (range) 0 (0) 0 (0–9)
  Mean ± SD 0 ± 0 1.9 ± 3.2 0.017
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mechanisms could explain this observation. Firstly, the 
pronounced skin reaction may be due to sensitization 
to Malassezia globosa and a true IgE-mediated Type I 
allergy to Malassezia globosa. This may be facilitated by 
sweat, components of which have been shown to increase 
the growth rate of Malassezia globosa [32]. Alternatively, 
sensitization to Malassezia could have a direct action on 
mast cells, increasing histamine content and interleu-
kin-6 production [33], and thereby augmenting hista-
mine release caused by other activation mechanisms. A 
combination of these two mechanisms is also possible. To 
answer these questions, functional test using basophils or 
mast cells would be needed, and should be performed in 
the future.
The more pronounced skin reactions in the ASwST on 
the other hand cannot be explained with a general hyper-
reactive skin in the supMGL_1304 sensibilized patients, 
as their reactivity to histamine per se, did not show any 
detectable differences. Also no correlation with the ASST 
has been seen.
Overall, there was a high number of patients, who 
showed positive reactions in the ASwSt, but had no 
detectable sensitizations to the analyzed fungi. This may 
be due to sensitization to yet unidentified sweat antigens, 
directly mast cell-activating factors, or histamine or simi-
lar mediators that are contained in the sweat of patients 
with CholU.
Sensitization to supMGL_1304 was strongly associ-
ated with atopic skin features and total IgE levels, but 
not with sensitization to common airborne/inhalant 
allergens. This is consistent with previous studies that 
showed a high rate of atopy in CholU patients [12, 34] 
and sensitization to supMGL_1304 in both CholU and 
atopic dermatitis patients [35]. This association fits the 
hypothesis that defects in the skin barrier could facilitate 
antigen uptake and subsequent sensitization [36]. Also, 
the microbes themselves could induce skin barrier 
defects that in turn initiate the sensitization [37], leading 
to a reinforcing feed-back loop.
Clinically, sensitization to supMGL_1304 was associ-
ated with higher symptom scores in the pulse-controlled 
ergonometry test, specifically itch. The reason for this 
remains unclear and warrants further investigation. To 
our knowledge, no other publication has reported such a 
correlation.
In our small cohort of four patients with elevated IgE 
levels to supMGL_1304, all patients were female. This 
was unexpected, as greater skin colonization by Malasse-
zia globosa has been reported in males [31]. However, 
atopy has been associated with female sex in CholU 
patients [12], and we have shown a strong correlation 
between IgE against supMGL_1304 and atopy in our 
study. Overall, the number of patients sensibilised to sup-
MGL_1304 was low and significant conclusions cannot 
be drawn. No correlation was seen with other assessed 
clinical factors such as age, disease persistance, frequency 
of symptoms or factors that trigger sweating.
The detection of specific IgE to Malassezia globosa 
raises the question of whether antimycotic treatment 
could be beneficial in CholU patients. In atopic derma-
titis, clinical studies have not provided any clear evi-
dence that antimycotic treatment leads to a significant 
improvement in symptoms [38, 39], but patients were 
usually not screened for sensitization to Malassezia glo-
bosa In CholU, desensitization therapy using autologous 
sweat or Malassezia globosa peptides has been shown to 
be beneficial for patients with intractable CholU due to 
sweat allergy [35, 40, 41]. Furthermore, intensified show-
ering or tannin acid have been proposed as therapeutic 







 ASST flare size diameter (mm) n = 20
  Median (range) 0 (0–4) 0 (0–19)
  Mean ± SD 10 ± 1.7 5.2 ± 8.9 0.075
 ACh i.c. pos (n) 1 (25%) 10 (47.6%) 0.604
 ACh i.c wheal size diameter (mm)
  Median (range) 0 (0–0.8) 0 (0–10)
  Mean ± SD 2.0 ± 1.2 3.1 ± 3.9 0.626
 ACh i.c. flare size diameter (mm)
  Median (range) 5.0 (5–55) 5.0 (0–35)
  Mean ± SD 19 ± 20.9 13.3 ± 1.6 0.0675
Statistical significant differences are shown in bold, trends in italics
ACh i.c. acetylcholine intracutaneous injection, ASwST autologous sweat skin test, ASST autologous serum skin test, BMI body mass index, CholUSI Cholinergic Urticaria 
Severity Index, Provo provocation, SD standard deviation, UAS urticaria activity score
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to Malassezia globosa [41]. Further work, including pla-
cebo-controlled studes, is needed in this area.
The main limitation of our study is the low number of 
CholU patients who displayed a sensitization to Malasse-
zia globosa Furthermore, data on the actual skin resi-
dency of skin fungi, their subspecies and numbers were 
not captured.
Conclusion
In summary, this study showed that a subgroup of Ger-
man Caucasian CholU patients displayed sensitization 
to skin resident fungi and that this sensitization was 
associated with atopic predisposition and more pro-
nounced skin reactions to sweat provocation tests. Anti-
fungal treatments could be a therapeutic option in these 
patients, if skin colonization with fungi is present and 
increased.
Abbreviations
ACh: Acetylcholine; ASST: Autologous serum skin test; ASwST: Autolo-
gous sweat skin test; AU: Arbitrary unit; CholU: Cholinergic urticaria; i.c.: 
Intracutaneous.
Acknowledgements
We want to thank Sophie Harms for administrative assistance.
Authors’ contributions
SA coordinated the study, collected patient data, was involved in statistical 
analysis and drafted the manuscript. YW was involved in data management. 
OA was involved in data management, statistical analysis and manuscript 
preparation. PS collected patient data and was involved in data management. 
MH conducted laboratory assessments of patient sera. MH provided lab mate-
rial and supervised the laboratory assessment, and was involved in manuscript 
preparation and proof-reading. MM was the overall study coordinator and was 
involved in manuscript preparation and proof-reading. All authors read and 
approved the final manuscript.
Funding
This study was supported by intramural funding of the Charité–Universitäts-
medizin Berlin, Germany.
Availability of data and materials
Raw data were generated at Charité–Universitätsmedizin Berlin, Germany. 
Derived data supporting the findings of this study are available from the cor-
responding author on request.
Ethics approval and consent to participate





Sabine Altrichter is or recently was a speaker and/or advisor for and/or has 
received research funding from Allakos, AstraZeneca, Moxie, Sanofi and 
Novartis. Yiyu Wang, Ola Alraboni, Pia Schumacher, Makiko Hiragun has no 
competing interests. Mchihiro Hide is or recently was a speaker and/or advisor 
for and/or has received research funding from. Marcus Maurer is or recently 
was a speaker and/or advisor for and/or has received research funding from 
Allakos, Aralez, Genentech, GSK, Menarini, Merckle Recordati, Moxie, Novartis, 
Sanofi, MSD, and Uriach.
Author details
1 Department of Dermatology and Allergy, Allergie-Centrum-Charité/ECARF, 
Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. 
2 Department of Dermatology, Integrated Health Sciences, Institute of Bio-
medical and Health Sciences, Hiroshima University, Hiroshima, Japan. 
Received: 9 March 2020   Accepted: 16 May 2020
References
 1. Magerl M, Altrichter S, Borzova E, Gimenez-Arnau A, Grattan CE, Lawlor 
F, et al. The definition, diagnostic testing, and management of chronic 
inducible urticarias—The EAACI/GA(2) LEN/EDF/UNEV consensus recom-
mendations 2016 update and revision. Allergy. 2016;71(6):780–802 (Epub 
2016/03/19).
 2. Kim JE, Eun YS, Park YM, Park HJ, Yu DS, Kang H, et al. Clinical character-
istics of cholinergic urticaria in Korea. Ann Dermatol. 2014;26(2):189–94 
(Epub 2014/06/03).
 3. Krupa Shankar DS, Ramnane M, Rajouria EA. Etiological approach to 
chronic urticaria. Indian J Dermatol. 2010;55(1):33–8 (Epub 2010/04/27).
 4. Moore-Robinson M, Warin RP. Some clinical aspects of cholinergic urti-
caria. Br J Dermatol. 1968;80(12):794–9 (Epub 1968/12/01).
 5. Godse K, Farooqui S, Nadkarni N, Patil S. Prevalence of cholinergic 
urticaria in Indian adults. Indian Dermatol Online J. 2013;4(1):62–3 (Epub 
2013/02/26).
 6. Zuberbier T, Althaus C, Chantraine-Hess S, Czarnetzki BM. Preva-
lence of cholinergic urticaria in young adults. J Am Acad Dermatol. 
1994;31(6):978–81 (Epub 1994/12/01).
 7. Asady A, Ruft J, Ellrich A, Hawro T, Maurer M, Altrichter S. Cholinergic 
urticaria patients of different age groups have distinct features. Clin Exp 
Allergy. 2017;47(12):1609–14 (Epub 2017/09/06).
 8. Ruft J, Asady A, Staubach P, Casale T, Sussmann G, Zuberbier T, et al. 
Development and validation of the Cholinergic Urticaria Quality-of-Life 
Questionnaire (CholU-QoL). Clin Exp Allergy. 2018;48(4):433–44 (Epub 
2018/01/26).
 9. Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of 
disability in different urticarial conditions. Br J Dermatol. 1999;140(4):667–
71 (Epub 1999/05/08).
 10. Horikawa T, Fukunaga A, Nishigori C. New concepts of hive formation in 
cholinergic urticaria. Curr Allergy Asthma Rep. 2009;9(4):273–9 (Epub 
2009/08/07).
 11. Bito T, Sawada Y, Tokura Y. Pathogenesis of cholinergic urticaria in relation 
to sweating. Allergol Int. 2012;61(4):539–44 (Epub 2012/10/25).
 12. Altrichter S, Koch K, Church MK, Maurer M. Atopic predisposition in 
cholinergic urticaria patients and its implications. J Eur Acad Dermatol 
Venereol. 2016;30(12):2060–5 (Epub 2016/06/22).
 13. Adachi J, Aoki T, Yamatodani A. Demonstration of sweat allergy in cholin-
ergic urticaria. J Dermatol Sci. 1994;7(2):142–9.
 14. Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment 
of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 
2008;63(2):247–9 (Epub 2008/01/12).
 15. Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al. Anti-
immunoglobulin E treatment of patients with recalcitrant physical urti-
caria. Int Arch Allergy Immunol. 2011;154(2):177–80 (Epub 2010/08/25).
 16. Hide M, Tanaka T, Yamamura Y, Koro O, Yamamoto S. IgE-mediated 
hypersensitivity against human sweat antigen in patients with atopic 
dermatitis. Acta Derm Venereol. 2002;82(5):335–40 (Epub 2002/11/15).
 17. Hiragun M, Hiragun T, Ishii K, Suzuki H, Tanaka A, Yanase Y, et al. Elevated 
serum IgE against MGL_1304 in patients with atopic dermatitis and 
cholinergic urticaria. Allergol Int. 2014;63(1):83–93.
 18. Hiragun T, Ishii K, Hiragun M, Suzuki H, Kan T, Mihara S, et al. Fungal 
protein MGL_1304 in sweat is an allergen for atopic dermatitis patients. J 
Allergy Clin Immunol. 2013;132(3):608–615.e4 (Epub 2013/06/04).
 19. Tanaka A, Tanaka T, Suzuki H, Ishii K, Kameyoshi Y, Hide M. Semi-purifica-
tion of the immunoglobulin E-sweat antigen acting on mast cells and 
basophils in atopic dermatitis. Exp Dermatol. 2006;15(4):283–90 (Epub 
2006/03/04).
 20. Takahagi S, Tanaka T, Ishii K, Suzuki H, Kameyoshi Y, Shindo H, et al. 
Sweat antigen induces histamine release from basophils of patients 
Page 9 of 9Altrichter et al. Clin Transl Allergy           (2020) 10:18  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
with cholinergic urticaria associated with atopic diathesis. Br J Dermatol. 
2009;160(2):426–8 (Epub 2008/09/25).
 21. Glatz M, Buchner M, von Bartenwerffer W, Schmid-Grendelmeier P, Worm 
M, Hedderich J, et al. Malassezia spp.-specific immunoglobulin E level is 
a marker for severity of atopic dermatitis in adults. Acta Derm Venereol. 
2015;95(2):191–6 Epub 2014/04/04.
 22. Maurer M, Metz M, Bindslev-Jensen C, Bousquet J, Canonica GW, Church 
MK, et al. Definition, aims, and implementation of GA(2) LEN Urticaria 
Centers of Reference and Excellence. Allergy. 2016;71(8):1210–8.
 23. Diepgen TL, Sauerbrei W, Fartasch M. Development and validation of 
diagnostic scores for atopic dermatitis incorporating criteria of data qual-
ity and practical usefulness. J Clin Epidemiol. 1996;49(9):1031–8.
 24. Koch K, Weller K, Werner A, Maurer M, Altrichter S. Antihistamine updos-
ing reduces disease activity in patients with difficult-to-treat cholinergic 
urticaria. J Allergy Clin Immunol. 2016;138(5):1483–1485.e9 (Epub 
2016/08/09).
 25. Altrichter S, Salow J, Ardelean E, Church MK, Werner A, Maurer M. Devel-
opment of a standardized pulse-controlled ergometry test for diagnosing 
and investigating cholinergic urticaria. J Dermatol Sci. 2014;75(2):88–93 
(Epub 2014/05/20).
 26. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, 
et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classifi-
cation, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–
414 (Epub 2018/01/18).
 27. Fukunaga A, Bito T, Tsuru K, Oohashi A, Yu X, Ichihashi M, et al. Respon-
siveness to autologous sweat and serum in cholinergic urticaria classifies 
its clinical subtypes. J Allergy Clin Immunol. 2005;116(2):397–402 (Epub 
2005/08/09).
 28. Kan T, Hiragun T, Ishii K, Hiragun M, Yanase Y, Tanaka A, et al. Evaluation of 
recombinant MGL_1304 produced by Pichia pastoris for clinical applica-
tion to sweat allergy. Allergol Int. 2015;64(3):266–71.
 29. Savolainen J, Lintu P, Kosonen J, Kortekangas-Savolainen O, Viander 
M, Pene J, et al. Pityrosporum and Candida specific and non-specific 
humoral, cellular and cytokine responses in atopic dermatitis patients. 
Clin Exp Allergy. 2001;31(1):125–34 (Epub 2001/02/13).
 30. Nowicka D, Nawrot U. Contribution of Malassezia spp. to the devel-
opment of atopic dermatitis. Mycoses. 2019;62(7):588–96 (Epub 
2019/03/26).
 31. Akaza N, Akamatsu H, Sasaki Y, Takeoka S, Kishi M, Mizutani H, et al. Cuta-
neous Malassezia microbiota of healthy subjects differ by sex, body part 
and season. J Dermatol. 2010;37(9):786–92 (Epub 2010/10/05).
 32. Akaza N, Akamatsu H, Takeoka S, Sasaki Y, Mizutani H, Nakata S, et al. 
Malassezia globosa tends to grow actively in summer conditions more 
than other cutaneous Malassezia species. J Dermatol. 2012;39(7):613–6 
(Epub 2012/01/11).
 33. Ribbing C, Engblom C, Lappalainen J, Lindstedt K, Kovanen PT, Karlsson 
MA, et al. Mast cells generated from patients with atopic eczema have 
enhanced levels of granule mediators and an impaired Dectin-1 expres-
sion. Allergy. 2011;66(1):110–9 (Epub 2010/07/09).
 34. Hirschmann JV, Lawlor F, English JS, Louback JB, Winkelmann RK, Greaves 
MW. Cholinergic urticaria. A clinical and histologic study. Arch Dermatol. 
1987;123(4):462–7 (Epub 1987/04/01).
 35. Hiragun T, Hiragun M, Ishii K, Kan T, Hide M. Sweat allergy: extrinsic or 
intrinsic? J Dermatol Sci. 2017;87(1):3–9 (Epub 2017/04/19).
 36. Schmid-Grendelmeier P, Scheynius A, Crameri R. The role of sensitiza-
tion to Malassezia sympodialis in atopic eczema. Chem Immunol Allergy. 
2006;91:98–109 (Epub 2005/12/16).
 37. Jinnestal CL, Belfrage E, Back O, Schmidtchen A, Sonesson A. Skin barrier 
impairment correlates with cutaneous Staphylococcus aureus coloniza-
tion and sensitization to skin-associated microbial antigens in adult 
patients with atopic dermatitis. Int J Dermatol. 2014;53(1):27–33 (Epub 
2013/07/25).
 38. Broberg A, Faergemann J. Topical antimycotic treatment of atopic derma-
titis in the head/neck area. A double-blind randomised study. Acta Derm 
Venereol. 1995;75(1):46–9 (Epub 1995/01/01).
 39. Wong AW, Hon EK, Zee B. Is topical antimycotic treatment useful as 
adjuvant therapy for flexural atopic dermatitis: randomized, double-blind, 
controlled trial using one side of the elbow or knee as a control. Int J 
Dermatol. 2008;47(2):187–91 (Epub 2008/01/24).
 40. Kozaru T, Fukunaga A, Taguchi K, Ogura K, Nagano T, Oka M, et al. Rapid 
desensitization with autologous sweat in cholinergic urticaria. Allergol 
Int. 2011;60(3):277–81 (Epub 2011/03/03).
 41. Shindo H, Takahagi S, Mihara S, Tanaka T, Ishii K, Hide M, et al. Efficacy of 
sweat-antigen-inactivating skin care products on itching of patients with 
atopic dermatitis. Arerugi. 2011;60(1):33–42 (Epub 2011/02/25).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
